AstraZeneca Plc has given a slightly more optimistic forecast for the bottom line this year and expressed confidence about a return to growth, as the last of its legacy products loses patent protection in Europe. The company still expects a decline in core earnings per share, but the fall is expected to be closer to 10% than to a mid-teen percentage decline.
